Conference Coverage

Conference Coverage Videos

Complete Conference Coverage

Study Highlights Importance of Achieving CR After Intensive Therapy for AML

Study Highlights Importance of Achieving CR After Intensive Therapy for AML

Patients with acute myeloid leukemia (AML) who achieve complete remission have improved overall survival.

No Induction Therapy Superior to Another for Higher-risk AML, MDS

No Induction Therapy Superior to Another for Higher-risk AML, MDS

In higher-risk patients who fail hypomethylating agent treatment, no induction strategy is superior to another with respect to outcomes and safety.

Condensed HDAC Schedule Superior to Standard Schedule in AML

Condensed HDAC Schedule Superior to Standard Schedule in AML

Consolidation therapy with a condensed schedule of high-dose cytarabine (HDAC) is superior to a standard schedule.

Higher Idarubicin Dose During Consolidation Improves Leukemia-free Survival in AML

Higher Idarubicin Dose During Consolidation Improves Leukemia-free Survival in AML

A higher dose of idarubicin during consolidation therapy improves leukemia-free survival without increasing non-hematologic toxicity.

Brentuximab Vedotin Superior to Standard of Care Options in CTCL

Brentuximab Vedotin Superior to Standard of Care Options in CTCL

Treatment with brentuximab vedotin is associated with superior clinical outcomes compared with standard of care options.

Chemo-free Induction Efficacious in Younger Patients With Mantle Cell Lymphoma

Chemo-free Induction Efficacious in Younger Patients With Mantle Cell Lymphoma

Chemotherapy-free induction with ibrutinib and rituximab is efficacious and well-tolerated among young patients.

VcR-CVAD Regimen Induces Durable Remissions in Mantle Cell Lymphoma

VcR-CVAD Regimen Induces Durable Remissions in Mantle Cell Lymphoma

Incorporation of bortezomib into VcR-CVAD followed by rituximab maintenance demonstrated high rates of durable remissions.

Rituximab Maintenance Prolongs Survival Among Younger Patients With Mantle Cell Lymphoma

Rituximab Maintenance Prolongs Survival Among Younger Patients With Mantle Cell Lymphoma

Rituximab maintenance following autologous hematopoietic cell transplantation prolongs survival among younger patients with mantle cell lymphoma.

Brentuximab Vedotin + RCHP Active in High-intermediate/High Risk DLBCL

Brentuximab Vedotin + RCHP Active in High-intermediate/High Risk DLBCL

Brentuximab vedotin in combination with RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) is active as a frontline therapy.

Study Identifies Ultra-high Risk Category of Patients With DLBCL

Study Identifies Ultra-high Risk Category of Patients With DLBCL

Ultra-high risk category of patients with diffuse large B-cell lymphoma (DLBCL) who have dismal outcomes on existing therapies.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs